Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristen Pollizzi

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Immunity|January 31, 2012
Fueling memoriesJonathan D Powell, Kristen Pollizzi
Molecular Cancer|June 17, 2009
Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosisKristen Pollizzi, Izabela Malinowska-Kolodziej, Michael Stumm, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 23, 2008
Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and functionLynsey Meikle, Kristen Pollizzi, Anna Egnor, et al.
Immunity|April 23, 2011
A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunityQingsheng Li, Rajesh R Rao, Koichi Araki, et al.
Human Molecular Genetics|April 10, 2009
A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 allelesKristen Pollizzi, Izabela Malinowska-Kolodziej, Cheryl Doughty, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 25, 2007
A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survivalLynsey Meikle, Delia M Talos, Hiroaki Onda, et al.
Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Immunity|January 31, 2012
Fueling memoriesJonathan D Powell, Kristen Pollizzi
Molecular Cancer|June 17, 2009
Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosisKristen Pollizzi, Izabela Malinowska-Kolodziej, Michael Stumm, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 23, 2008
Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and functionLynsey Meikle, Kristen Pollizzi, Anna Egnor, et al.
Immunity|April 23, 2011
A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunityQingsheng Li, Rajesh R Rao, Koichi Araki, et al.
Human Molecular Genetics|April 10, 2009
A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 allelesKristen Pollizzi, Izabela Malinowska-Kolodziej, Cheryl Doughty, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 25, 2007
A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survivalLynsey Meikle, Delia M Talos, Hiroaki Onda, et al.
Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.
Pageof 1